Extended Release Tacrolimus vs. Twice-Daily Tacrolimus
Status:
Active, not recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
The overall aim of the study is to prospectively investigate the impact of two maintenance
calcineurin inhibitor immunosuppressive regimens: once-daily extended release tacrolimus and
twice-daily tacrolimus on subpopulations of T and B cells and alloreactive T cells as well as
on renal allograft function.